(Q42544275)

2 November 2017

Hepatic responses to inhibition of 3-hydroxy-3-methylglutaryl-CoA reductase: a comparison of atorvastatin and simvastatin (English)

1 reference

2 November 2017

J D Bergstrom

1

1 reference

2 November 2017

R G Bostedor

2

1 reference

2 November 2017

D J Rew

3

1 reference

2 November 2017

W M Geissler

4

1 reference

2 November 2017

S D Wright

5

1 reference

2 November 2017

Y S Chao

6

1 reference

2 November 2017

1 January 1998

1 reference

Biochimica et Biophysica Acta

2 November 2017

9

1 reference

based on heuristic

inferred from page(s)

published in

1 reference

2 November 2017

1389

1 reference

2 November 2017

3

1 reference

2 November 2017

213-221

1 reference

Regulation of cholesterol synthesis in rat adrenal gland through coordinate control of 3-hydroxy-3-methylglutaryl coenzyme A synthase and reductase activities

2 November 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0005-2760%2897%2900182-3

Regulatory role for hepatic low density lipoprotein receptors in vivo in the dog

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0005-2760%2897%2900182-3

Regulation of the mevalonate pathway

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0005-2760%2897%2900182-3

Regulation of synthesis and degradation of 3-hydroxy-3-methylglutaryl-coenzyme A reductase by low density lipoprotein and 25-hydroxycholesterol in UT-1 cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0005-2760%2897%2900182-3

HMG-CoA reductase inhibitors for treatment of hypercholesterolemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0005-2760%2897%2900182-3

Simvastatin decreases the hepatic secretion of very-low-density lipoprotein apolipoprotein B-100 in heterozygous familial hypercholesterolaemia: pathophysiological and therapeutic implications

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0005-2760%2897%2900182-3

Cholesterol is required for secretion of very-low-density lipoprotein by rat liver

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0005-2760%2897%2900182-3

Efficacy and safety of a new HMG-CoA reductase inhibitor, atorvastatin, in patients with hypertriglyceridemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0005-2760%2897%2900182-3

Antiatherosclerotic activity of inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A reductase in cholesterol-fed rabbits: a biochemical and morphological evaluation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0005-2760%2897%2900182-3

Lipid-lowering activity of atorvastatin and lovastatin in rodent species: triglyceride-lowering in rats correlates with efficacy in LDL animal models

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0005-2760%2897%2900182-3

Comparative effects of HMG-CoA reductase inhibitors on apo B production in the casein-fed rabbit: atorvastatin versus lovastatin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0005-2760%2897%2900182-3

Pharmacodynamic effects and pharmacokinetics of atorvastatin after administration to normocholesterolemic subjects in the morning and evening

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0005-2760%2897%2900182-3

Effect of age and gender on pharmacokinetics of atorvastatin in humans.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0005-2760%2897%2900182-3

Effect of food on the bioavailability of atorvastatin, an HMG-CoA reductase inhibitor.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0005-2760%2897%2900182-3

Tolerance and pharmacokinetics of single-dose atorvastatin, a potent inhibitor of HMG-CoA reductase, in healthy subjects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0005-2760%2897%2900182-3

Comparative pharmacokinetics of lovastatin, simvastatin and pravastatin in humans

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0005-2760%2897%2900182-3

The efficacy and six-week tolerability of simvastatin 80 and 160 mg/day

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0005-2760%2897%2900182-3

Tissue selectivity of the cholesterol-lowering agents lovastatin, simvastatin and pravastatin in rats in vivo

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0005-2760%2897%2900182-3

Regulation of HMG-CoA reductase, apoprotein-B and LDL receptor gene expression by the hypocholesterolemic drugs simvastatin and ciprofibrate in Hep G2, human and rat hepatocytes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0005-2760%2897%2900182-3

The effect of HMG-CoA reductase inhibitor (CS-514) on the synthesis and secretion of apolipoproteins B and A-1 in the human hepatoblastoma Hep G2

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0005-2760%2897%2900182-3

Butyrate stimulates the secretion of apolipoprotein (apo) A-I and apo B100 by the human hepatoma cell line Hep G2. Induction of apo A-I mRNA with no change of apo B100 mRNA.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0005-2760%2897%2900182-3

Butyrate stimulates the secretion of apolipoprotein B-100-containing lipoproteins from HepG2 cells by inhibiting the intracellular degradation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0005-2760%2897%2900182-3

10.1016/S0005-2760(97)00182-3

7 January 2021

Identifiers

DOI

1 reference

2 November 2017

1 reference